335 related articles for article (PubMed ID: 16443877)
1. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.
Baillargeon JP; Diamanti-Kandarakis E; Ostlund RE; Apridonidze T; Iuorno MJ; Nestler JE
Diabetes Care; 2006 Feb; 29(2):300-5. PubMed ID: 16443877
[TBL] [Abstract][Full Text] [Related]
2. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism.
Baillargeon JP; Nestler JE; Ostlund RE; Apridonidze T; Diamanti-Kandarakis E
Hum Reprod; 2008 Jun; 23(6):1439-46. PubMed ID: 18375940
[TBL] [Abstract][Full Text] [Related]
3. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome.
Cheang KI; Baillargeon JP; Essah PA; Ostlund RE; Apridonize T; Islam L; Nestler JE
Metabolism; 2008 Oct; 57(10):1390-7. PubMed ID: 18803944
[TBL] [Abstract][Full Text] [Related]
4. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.
Baillargeon JP; Iuorno MJ; Jakubowicz DJ; Apridonidze T; He N; Nestler JE
J Clin Endocrinol Metab; 2004 Jan; 89(1):242-9. PubMed ID: 14715857
[TBL] [Abstract][Full Text] [Related]
5. Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity.
Villeneuve MC; Ostlund RE; Baillargeon JP
Metabolism; 2009 Jan; 58(1):62-8. PubMed ID: 19059532
[TBL] [Abstract][Full Text] [Related]
6. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
Baillargeon JP; Iuorno MJ; Apridonidze T; Nestler JE
Metab Syndr Relat Disord; 2010 Apr; 8(2):127-36. PubMed ID: 20156067
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome.
Gupta A; Jakubowicz D; Nestler JE
Metab Syndr Relat Disord; 2016 Oct; 14(8):391-396. PubMed ID: 27028341
[TBL] [Abstract][Full Text] [Related]
8. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
[TBL] [Abstract][Full Text] [Related]
9. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Galazis N; Galazi M; Atiomo W
Gynecol Endocrinol; 2011 Apr; 27(4):256-62. PubMed ID: 21142777
[TBL] [Abstract][Full Text] [Related]
10. Effect on Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator during Weight Loss in Obese Women with and without Polycystic Ovary Syndrome.
Cheang KI; Sistrun SN; Morel KS; Nestler JE
Int J Endocrinol; 2016; 2016():7631804. PubMed ID: 27721826
[No Abstract] [Full Text] [Related]
11. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Croze ML; Soulage CO
Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
[TBL] [Abstract][Full Text] [Related]
12. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
Nestler JE; Jakubowicz DJ; Iuorno MJ
J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1295-8. PubMed ID: 11117673
[TBL] [Abstract][Full Text] [Related]
13. Reflections on inositol(s) for PCOS therapy: steps toward success.
Nestler JE; Unfer V
Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
[TBL] [Abstract][Full Text] [Related]
14. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Genazzani AD; Santagni S; Rattighieri E; Chierchia E; Despini G; Marini G; Prati A; Simoncini T
Gynecol Endocrinol; 2014 Jun; 30(6):438-43. PubMed ID: 24601829
[TBL] [Abstract][Full Text] [Related]
15. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
[TBL] [Abstract][Full Text] [Related]
16. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Kachhawa G; Senthil Kumar KV; Kulshrestha V; Khadgawat R; Mahey R; Bhatla N
Int J Gynaecol Obstet; 2022 Aug; 158(2):278-284. PubMed ID: 34624138
[TBL] [Abstract][Full Text] [Related]
18. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
Nordio M; Basciani S; Camajani E
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
[TBL] [Abstract][Full Text] [Related]
19. Potential role of d-
Simic D; Nikolic Turnic T; Dimitrijevic A; Zivadinovic A; Milosevic-Stevanovic J; Djuric D; Zivkovic V; Jakovljevic V
Can J Physiol Pharmacol; 2022 Jul; 100(7):629-636. PubMed ID: 35413205
[TBL] [Abstract][Full Text] [Related]
20. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome.
Donà G; Sabbadin C; Fiore C; Bragadin M; Giorgino FL; Ragazzi E; Clari G; Bordin L; Armanini D
Eur J Endocrinol; 2012 Apr; 166(4):703-10. PubMed ID: 22223702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
